Scandion Oncology A/S (SCOL) - Total Assets
Based on the latest financial reports, Scandion Oncology A/S (SCOL) holds total assets worth Skr18.28 Million SEK (≈ $1.97 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check SCOL cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Scandion Oncology A/S - Total Assets Trend (2017–2024)
This chart illustrates how Scandion Oncology A/S's total assets have evolved over time, based on quarterly financial data. Check SCOL intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Scandion Oncology A/S - Asset Composition Analysis
Current Asset Composition (December 2024)
Scandion Oncology A/S's total assets of Skr18.28 Million consist of 99.2% current assets and 0.8% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 69.4% |
| Accounts Receivable | Skr807.00K | 4.4% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Scandion Oncology A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SCOL company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scandion Oncology A/S's current assets represent 99.2% of total assets in 2024, an increase from 98.2% in 2017.
- Cash Position: Cash and equivalents constituted 69.4% of total assets in 2024, down from 83.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 4.4% of total assets.
Scandion Oncology A/S Competitors by Total Assets
Key competitors of Scandion Oncology A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Scandion Oncology A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.81 | 9.79 | 10.49 |
| Quick Ratio | 1.81 | 9.79 | 10.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr8.13 Million | Skr30.23 Million | Skr14.53 Million |
Scandion Oncology A/S - Advanced Valuation Insights
This section examines the relationship between Scandion Oncology A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.08 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -47.1% |
| Total Assets | Skr18.28 Million |
| Market Capitalization | $103.58K USD |
Valuation Analysis
Below Book Valuation: The market values Scandion Oncology A/S's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Scandion Oncology A/S's assets decreased by 47.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Scandion Oncology A/S (2017–2024)
The table below shows the annual total assets of Scandion Oncology A/S from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr18.28 Million ≈ $1.97 Million |
-47.11% |
| 2023-12-31 | Skr34.56 Million ≈ $3.72 Million |
-61.34% |
| 2022-12-31 | Skr89.40 Million ≈ $9.62 Million |
-23.08% |
| 2021-12-31 | Skr116.22 Million ≈ $12.51 Million |
-37.65% |
| 2020-12-31 | Skr186.41 Million ≈ $20.06 Million |
+836.60% |
| 2019-12-31 | Skr19.90 Million ≈ $2.14 Million |
+46.74% |
| 2018-12-31 | Skr13.56 Million ≈ $1.46 Million |
+591.35% |
| 2017-12-31 | Skr1.96 Million ≈ $211.12K |
-- |
About Scandion Oncology A/S
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for tr… Read more